169 related articles for article (PubMed ID: 31262032)
1. Trifluoperazine, an Antipsychotic Drug, Effectively Reduces Drug Resistance in Cisplatin-Resistant Urothelial Carcinoma Cells via Suppressing Bcl-xL: An In Vitro and In Vivo Study.
Kuo KL; Liu SH; Lin WC; Hsu FS; Chow PM; Chang YW; Yang SP; Shi CS; Hsu CH; Liao SM; Chang HC; Huang KH
Int J Mol Sci; 2019 Jun; 20(13):. PubMed ID: 31262032
[TBL] [Abstract][Full Text] [Related]
2. MLN4924 Synergistically Enhances Cisplatin-induced Cytotoxicity via JNK and Bcl-xL Pathways in Human Urothelial Carcinoma.
Ho IL; Kuo KL; Liu SH; Chang HC; Hsieh JT; Wu JT; Chiang CK; Lin WC; Tsai YC; Chou CT; Hsu CH; Pu YS; Shi CS; Huang KH
Sci Rep; 2015 Nov; 5():16948. PubMed ID: 26592553
[TBL] [Abstract][Full Text] [Related]
3. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
[TBL] [Abstract][Full Text] [Related]
4. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides.
Lebedeva I; Raffo A; Rando R; Ojwang J; Cossum P; Stein CA
J Urol; 2001 Aug; 166(2):461-9. PubMed ID: 11458048
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
Cha HY; Lee BS; Chang JW; Park JK; Han JH; Kim YS; Shin YS; Byeon HK; Kim CH
Cancer Lett; 2016 Mar; 372(1):65-74. PubMed ID: 26721202
[TBL] [Abstract][Full Text] [Related]
7. Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.
Höhn A; Krüger K; Skowron MA; Bormann S; Schumacher L; Schulz WA; Hoffmann MJ; Niegisch G; Fritz G
Oncotarget; 2016 Jul; 7(27):41320-41335. PubMed ID: 27191498
[TBL] [Abstract][Full Text] [Related]
8. Emodin enhances cisplatin-induced cytotoxicity in human bladder cancer cells through ROS elevation and MRP1 downregulation.
Li X; Wang H; Wang J; Chen Y; Yin X; Shi G; Li H; Hu Z; Liang X
BMC Cancer; 2016 Aug; 16():578. PubMed ID: 27485374
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the Molecular Mechanism Underlying the Inhibitory Efficacy of Taiwanese Local Pomegranate Peels against Urinary Bladder Urothelial Carcinoma.
Chang CP; Chan YY; Li CF; Chien LH; Lee ST; Wu TF
Nutrients; 2018 Apr; 10(5):. PubMed ID: 29702555
[TBL] [Abstract][Full Text] [Related]
10. Enhanced inhibition of bladder cancer cell growth by simultaneous knockdown of antiapoptotic Bcl-xL and survivin in combination with chemotherapy.
Kunze D; Erdmann K; Froehner M; Wirth MP; Fuessel S
Int J Mol Sci; 2013 Jun; 14(6):12297-312. PubMed ID: 23749114
[TBL] [Abstract][Full Text] [Related]
11. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis.
Liu JR; Fletcher B; Page C; Hu C; Nunez G; Baker V
Gynecol Oncol; 1998 Sep; 70(3):398-403. PubMed ID: 9790794
[TBL] [Abstract][Full Text] [Related]
12. Bcl-XL small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma cells.
Lei X; Huang Z; Zhong M; Zhu B; Tang S; Liao D
Acta Biochim Biophys Sin (Shanghai); 2007 May; 39(5):344-50. PubMed ID: 17492131
[TBL] [Abstract][Full Text] [Related]
13. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
14. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer.
Mu P; Nagahara S; Makita N; Tarumi Y; Kadomatsu K; Takei Y
Int J Cancer; 2009 Dec; 125(12):2978-90. PubMed ID: 19422046
[TBL] [Abstract][Full Text] [Related]
15. Sensitization of cisplatin resistant bladder tumor by combination of cisplatin treatment and co-culture of dendritic cells with apoptotic bladder cancer cells.
Zhang Q; Chen Z
Cell Mol Biol (Noisy-le-grand); 2018 Jul; 64(10):102-107. PubMed ID: 30084800
[TBL] [Abstract][Full Text] [Related]
16. Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines.
Skowron MA; Melnikova M; van Roermund JGH; Romano A; Albers P; Thomale J; Schulz WA; Niegisch G; Hoffmann MJ
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29462944
[TBL] [Abstract][Full Text] [Related]
17. Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Lin WC; Hsu FS; Kuo KL; Liu SH; Shun CT; Shi CS; Chang HC; Tsai YC; Lin MC; Wu JT; Kuo Y; Chow PM; Liao SM; Yang SP; Hong JY; Huang KH
J Mol Med (Berl); 2018 Dec; 96(12):1307-1318. PubMed ID: 30288546
[TBL] [Abstract][Full Text] [Related]
18. Trifluoperazine Activates FOXO1-Related Signals to Inhibit Tumor Growth in Hepatocellular Carcinoma.
Jiang J; Huang Z; Chen X; Luo R; Cai H; Wang H; Zhang H; Sun T; Zhang Y
DNA Cell Biol; 2017 Oct; 36(10):813-821. PubMed ID: 28876084
[TBL] [Abstract][Full Text] [Related]
19. The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL.
Sun Q; Yogosawa S; Iizumi Y; Sakai T; Sowa Y
Int J Oncol; 2015 Jan; 46(1):389-94. PubMed ID: 25310746
[TBL] [Abstract][Full Text] [Related]
20. Optimizing chemotherapy for transitional cell carcinoma by application of bcl-2 and bcl-xL antisense oligodeoxynucleotides.
Bolenz C; Becker A; Trojan L; Schaaf A; Cao Y; Weiss C; Alken P; Michel MS
Urol Oncol; 2007; 25(6):476-82. PubMed ID: 18047955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
